No headlines found.
Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
PRNewswire (Thu, 13-Nov 7:30 AM ET)
PRNewswire (Wed, 12-Nov 12:15 PM ET)
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. The Company's business is in one operating segment: life science.
Palatin Techs trades on the AMEX stock market under the symbol PTN.
As of February 2, 2026, PTN stock price climbed to $17.25 with 32,204 million shares trading.
PTN has a market cap of $29.37 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that PTN belongs to (by Net Assets): VXF.
PTN support price is $13.23 and resistance is $16.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PTN shares will trade within this expected range on the day.